Filing Details
- Accession Number:
- 0001209191-24-001269
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-01-09 18:00:35
- Reporting Period:
- 2024-01-06
- Accepted Time:
- 2024-01-09 18:00:35
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1070494 | Acadia Pharmaceuticals Inc | ACAD | Pharmaceutical Preparations (2834) | 061376651 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1131146 | Stephen Davis | C/O Acadia Pharmaceuticals Inc. 12830 El Camino Real, Suite 400 San Diego CA 92130 | Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-01-06 | 9,528 | $0.00 | 100,253 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-01-08 | 3,732 | $29.96 | 96,521 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2024-01-06 | 9,528 | $0.00 | 9,528 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | M | Direct |
Footnotes
- Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
- Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. On October 6, 2023, the Reporting Person filed a Form 4 which reported the same acquisition of shares in a footnote to Table I, Column 5, but inadvertently omitted such shares from the total in Table I, Column 5. The May 15, 2023 acquisition by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan is now correctly included in Table I, Column 5 of this Form 4.
- The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
- The restricted stock units vest in four equal annual installments beginning January 6, 2021.
Billionaire Hedge Funds
